Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

Debiopharm announces the poster presentations of preclinical data for Debio0123 and clinical data for Debio1143 and Debio1347 – Debiopharm, ( ) a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio1347 (FGFR inhibitor) and clinical exploratory results for Debio1143 (IAP inhibitor) at the 2019 Annual AACR meeting in Atlanta, Georgia. These abstract presentations are part of Debiopharm’s ongoing oncology programs to investigate the anti-tumor activity and toxicity profile of innovative compounds aimed at treating a broad variety of cancer types. Lausanne, Switzerland – April 1, 2019 www.debiopharm.com/debiopharm-international/ [1] “These results from our multiple ongoing oncology programs are giving us more insight into the potential of integrating specialized, targeted compounds into current therapeutic strategies.” – Gregoire Vuagniaux, Director of Translational Pharmacology, Debiopharm International SA AACR 2019 Abstract Presentations Debio0123 Abstract n°4423: Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio0123 Date and Time: Tue, April 2nd, 1:00-5:00pm Debio1143 Abstract n°5001: Open-label, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the SMAC mimetic Debio1143 in patients with resectable squamous cell carcinoma of the head and neck Date and Time: Wed, April 3rd, 8:00-12:00pm Debio1347 Abstract n°4881: Molecular screening of patients with FGFR alterations for a phase 1 (ph1) study with the selective FGFR inhibitor (FGFRi) Debio1347 Date and Time: Wed, April 3rd, 8:00-12:00pm – Section 19 Debiopharm International’s commitment to cancer patients Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing and clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Find out about our currently clinical trials at patients.debiopharm.com Visit us www.debiopharm.com/debiopharm-international/ Follow us @DebiopharmNews IAP= Inhibitor of Apoptosis Proteins [1]

The release as fetched from its publisher. debiopharm.com ↗